Effective Date: February 5, 2021
Galectin Therapeutics Inc. (“Galectin Therapeutics” or the “Company”) provides the materials on this website for general information and educational purposes. This website contains information concerning the Galectin Therapeutics NAVIGATE Study clinical trial of belapectin for the prevention of esophageal varices in NASH cirrhosis (NCT04365868) which may be useful to potential patients with NASH cirrhosis, physicians treating patients with NASH cirrhosis, our collaborators and trial investigators, as well as the general public.
This site is intended for educational and informational purposes only and should not be considered a program for patient recruitment or patient enrollment in the trial. Patients considering participation in the trial should discuss their possible participation with their physicians.
Please read the following Terms and Conditions carefully. These Terms and Conditions (the “Terms”) apply to your access to, and use of, this website. By accessing, viewing or using this website, you agree to be bound by these Terms and Conditions. If you do not agree to be bound by these Terms and Conditions, you must stop accessing or using this website. We reserve the right to revise any or all of these Terms and Conditions, at any time and without notice, by posting the updated terms. Your use of this website is subject to any such revisions, and you should periodically visit this page to review the current Terms and Conditions which are applicable to your use of our website.
Galectin Therapeutics makes no representations or warranties and assumes no liability as to the accuracy, completeness, reliability or usefulness of any information contained on this website. Further, Galectin Therapeutics expressly disclaims any obligation to update or correct information contained on this website and explicitly disclaims any duty to do so. Galectin Therapeutics assumes no liability or responsibility for any errors or omissions in the content of this website. We reserve the right to change or modify the information or materials on this website at any time and in any way, without notice.
Nothing on this website constitutes or is intended to constitute an invitation or offer to invest or deal in the securities of Galectin Therapeutics.
Subject to your compliance with the Terms, Galectin Therapeutics grants you a limited non-exclusive, non-transferable, non-assignable and non-sublicensable license to access and use the Website for your own personal use only, and not for use for any business purpose or commercial activity. This license is granted for the sole purpose of enabling you to use and enjoy the benefit of the Website as provided by Galectin, in the manner permitted by the Terms.
This website contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors – many beyond our control – that could cause actual events or results to be significantly different from those described in the forward-looking statement. Any or all of the Company’s forward-looking statements in this website, its reports or in any other public statements the Company makes may turn out to be wrong. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. They use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or words of similar meaning. They may also use words such as “will,” “would,” “should,” “could,” or “may.” The actual results of the Company or the NAVIGATE Study could differ materially from the results contemplated by these forward-looking statements. Among the factors that could cause actual results to differ materially are uncertainties as to whether the objectives in the NAVIGATE Study can be achieved, whether belapectin has the therapeutic result that is desired, and whether NAVIGATE Study will lead ultimately to regulatory approval of this drug candidate.
These and other risks and uncertainties that could affect our actual results are discussed in greater detail in the Company’s recent filings with the Securities and Exchange Commission, including its reports on Form 8-K, 10-Q and 10-K. For a discussion of additional factors impacting our business, please see the Company’s most recent Annual Report on Form 10-K and our subsequent filings with the SEC.
The Company does not assume responsibility for the accuracy or completeness of these forward-looking statements. Furthermore, we do not undertake any duty to update any forward-looking statements or to publicly announce any revisions that we may make.
LINKS TO THIS WEBSITE AND USE OF OUR MARKS. You are hereby granted a non-exclusive, limited, and revocable license to link to this website. We reserve the right to revoke this license generally, or your right to use specific links, at any time. If we revoke this license, you agree to remove and disable any and all of your links to this website immediately.
You agree not to present the link to this website in such a way that it is associated with advertising or appears to be an endorsement of any organization, product, or service. You agree that the link will not appear on a website that a reasonable person may consider obscene, defamatory, harassing, grossly offensive, or malicious. Under no circumstances may you “frame” this website or any of its content or copy portions of this website to a server. You agree not to display or use our logos or trademarks in any manner without our prior written permission.
Any time you access or use the Website, you are required to comply with our User Conduct Guidelines, as set forth below. You may not: